Universal DX Initiates Clinical Trial for FDA Approval of Signal-C® Colorectal Cancer Screening Blood Test (Business Wire)

Universal DX has initiated a clinical trial for FDA approval of its Signal-C® blood test, designed for early colorectal cancer screening. The trial aims to validate the test’s effectiveness in detecting colorectal cancer at early stages, offering a non-invasive alternative to traditional screening methods. This step is crucial for bringing the test to market, potentially improving early detection rates and patient outcomes.